1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2020 https://goldcopd.org/

2. Eisner M.D., Anthonisen N., Coultas D. et al. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 182: 693 - 718.

3. Lamprecht B., McBurnie M.A., Vollmer W.M., et al., BOLD Collaborative Research Group: COPD in never smokers: results form the population-based burden of obstructive lung disease study. Chest 2011; 139: 752 - 763.

4. Mehta A.J., Miedinger D., Keidel D. et al., The SAPALDIA Team. Occupational exposure to dusts, gases, and fumes and incidence of chronic obstructive pulmonary disease in the Swiss Cohort Study on Air Pollution and Lung and Heart Diseases in Adults. Am J Respir Crit Care Med 2012; 185: 1292 - 1300.

5. Silva G.E., Sherrill D.L., Guerra S. et al. Asthma as a risk factor for COPD in a longitudinal study. Chest 2004; 126: 59 - 65.

6. Brutsche M.H., Downs S.H., Schindler C., Gerbase M.W., Schwartz J., Frey M., Russi E.W., Ackermann-Liebrich U., Leuenberger P.: Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA cohort study. Thorax 2006; 61: 671 - 677.

7. de Marco R., Accordini S., Marcon A., Cerveri I., J.M., Gislason T., Heinrich J., Janson C., Jarvis D., Kuenzli N., Leynaert B., Sunyer J., Svanes C., Wjst M., Burney P., European Community Respiratory Health Survey (ECRHS): Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults. Am J Respir Crit Care Med 2011; 183: 891 - 897.

8. de Marco R., Accordini S., Cerveri I., Corsico A., J.M., N., Janson C., Sunyer J., Jarvis D., Chinn S., Vermeire P., Svanes C., Ackermann-Liebrich U., Gislason T., Heinrich J., Leynaert B., Neukirch F., Schouten J.P., Wjst M., Burney P.: Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am J Respir Crit Care Med 2007; 175: 32 - 39.

9. Bridevaux P.O., Gerbase M.W., Probst-Hensch N.M., Schindler C., Gaspoz J.M., Rochat T.: Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD. Thorax 2008; 63: 768 - 774.

10. Stoller J.K.: Clinical features and natural history of severe alpha-1-antitrypsin deficiency. Chest 1997; 111: 123S - 128S.

11. Stoller J.K., Aboussouan L.S.: A review of alpha-1-antitrypsin deficiency. Am J Respir Crit Care Med 2012; 185: 246 - 259.

12. Smolonska J., Wijmenga C., Postma D.S., Boezen H.M.: Meta-analyses on suspected chronic obstructive pulmonary disease genes: a summary of 20 years' research. Am J Respir Crit Care Med 2009; 180: 618 - 631.

13. Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation//Int J COPD 2014; 12: 963 - 74.

14. World Health Organization. Evidence-informed policy-making. 2016. http://www.who.int/evidence

15. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2011//www.goldcopd.com.

16. Celli B., MacNee W., ATS/ERS Task Force: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932 - 946.

17. Bestall J.C., Paul E.A., Garrod R., Garnham R., Jones P.W., Wedzicha J.A.: Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 581 - 586.

18. Jones P.W., Harding G., Berry P., Wiklund I., Chen W.H., Kline Leidy N.: Development and first validation of the COPD Assessment Test. Eur Respir J 2009; 34: 648 - 654.

19. Hurst J.R., Vestbo J., Anzueto A., Locantore N., H., Tal-Singer R., Miller B., Lomas D.A., Agusti A., Macnee W., Calverley P., Rennard S., Wouters E.F., Wedzicha J.A.: Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128 - 1138.

20. Barnes P.J., Celli B.R.: Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33: 1165 - 1185.

21. Hill K., Goldstein R.S., Guyatt G.H. et al. Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care//CMAJ 2010; 182(7): 673 - 8.

22. G, Brenner S, Angermann CE, et al. "GOLD or lower limit of normal definition? A comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study". Respir Res. 2012; 13(1): 13. Published 2012 Feb 6. doi: 10.1186/1465-9921-13-13

23. Bhatt SP, Balte PP, Schwartz JE, Cassano PA, Couper D, Jacobs DR Jr, Kalhan R, O"Connor GT, Yende S, Sanders JL, Umans JG, Dransfield MT, Chaves PH, White WB, Oelsner EC. Discriminative Accuracy of FEV1: FVC Thresholds for COPD-Related Hospitalization and Mortality. JAMA. 2019 Jun 25; 321(24): 2438 - 2447. doi: 10.1001/jama.2019.7233. PMID: 31237643; PMCID: PMC6593636.

24. Tashkin D.P., Celli B., Decramer M., Liu D., Burkhart D., Cassino C. et al. Bronchodilator responsiveness in patients with COPD//Eur Respir J 2008; 31: 742 - 50.

25. Quanjer P.H., Tammeling G.J., Cotes J.E. et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European 80 Community for Steel and Coal. Official Statement of the European Respiratory Society//Eur Respir J. 1993, 6: suppl. 16, 5 - 40.

26. Wanger J., Clausen J.L., Coates A. et al. Standardisation of the measurement of lung volumes//Eur Respir J 2005; 26: 511 - 522.

27. Amalakanti S., Pentakota M.R. Pulse Oximetry Overestimates Oxygen Saturtion in COPD//Respir Care 2016; 61(4): 423 - 7.

28. Casanova C., Cote C.G., Marin J.M. et al. Test 6-min walking distance: long-term follow up in patients with COPD//Eur Respir J 2007; 29(3): 535 - 40.

29. Oga T., Nishimura K., Tsukino M. et al. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status//Am J Respir Crit Care Med 2003; 167(4): 544 - 9.

30. Kelly A.M., McAlpine R., Kyle E. How accurate are pulse oximeters in patients with acute exacerbationsof chronic obstructive airways disease? Respir Med 2001; 95 (5): 336 - 40.

31. Stoller J.K., Brantly M. The challenge of detecting alpha-1 antitrypsin deficiency//COPD 2013; 10(S1): 24 - 34.

32. Flenley D.C., Sleep in chronic obstructive lung disease//Clinics in Chest Medicine 1985 V. 4 S. 6. P. 651 - 661

33. Буниатян М.С., Зелвеян П.А., Ощепкова Е.В. Возможности мониторной пульсоксиметрии для скрининговой диагностики синдрома апноэ/гипопноэ во сне//Терапевтический архив 2002. Т. 74 N 11. С. 90 - 94.

34. Celli B., Cote C., Marin J., Casanova C., Montes de Oca M., Mendez R.A., Pinto Plata V., Cabral H.J.: The body mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005 - 1012.

35. Global Strategy for Asthma Management and Prevention. Revised 2017//www.ginasthma.com.

36. Albert P., Agusti A., Edwards L., Tal-Singer R., Yates J., Bakke P. et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax 2012; 67: 701 - 8.

37. Woolcock A.J. Corticosteroid-resistant asthma. Definitions. Am J Respir Crit Care Med 1996; 154: S45 - 8.

38. Pelkonen M., Notkola I.L., Tukiainen H., Tervahauta M., Toumilehto J., Nissinen A.: Smoking cessation, decline in pulmonary function and total mortality: a 30-year follow-up study among the Finnish cohorts of the Seven Countries Study. Thorax 2001; 56: 703 - 707.

39. Chandler M.A., Rennard S.I.: Smoking cessation. Chest 2010; 137: 428 - 435.

40. Henningfield J.E.: Nicotine medications for smoking cessation. N Engl J Med 1995; 333: 1196 - 1203.

41. Jorenby D.E., Leischow S.J., Nides M.A., Rennard S.I., Johnston J.A., Hughes A.R., Smith S.S., Muramoto M.L., Daughton D.M., Doan K., Fiore M.C., Baker T.B.: A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 685 - 691.

42. Silagy C., Mant D., Fowler G., Lodge M.: Metaanalysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet 1994; 343: 139 - 142.

43. Tashkin D., Kanner R., Bailey W., Buist S., Anderson P., Nides M., Gonzales D., Dozier G., Patel M.K., Jamerson B.: Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001; 357: 1571 - 1575.

44. Strassmann R., Bausch B., Spaar A., Kleijnen J., Braendli O., Puhan M.A.: Smoking cessation interventions in COPD: a network metaanalysis of randomised trials. Eur Respir J 2009; 34: 634 - 640.

45. Faessel H., Ravva P., Williams K.: Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: a multicenter, randomized, double-blind, placebocontrolled, parallel-group study. Clin Ther 2009; 31: 177 - 189.

46. Anthonisen N.R., Connett J.E., Kiley J.P., Altose M.D., Bailey W.C., Buist A.S., Conway W.A. Jr., Enright P.L., Kanner R.E., O'Hara P.: Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV 1. The Lung Health Study. JAMA 1994; 272: 1497 - 1505.

47. Decramer M., Celli B., Kesten S., Lystig T., Mehra S., Tashkin D.P. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171 - 8.

48. Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009; 10: 59.

49. Lipson DA, Crim C, Criner GJ, et al., Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2020 Jun 15; 201(12): 1508 - 1516.

50. Sestini P., Renzoni E., Robinson S., Poole P., Ram F.S.F. Short-acting beta2-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002; 3: CD001495.

51. Chung V.C.H., Ma P.H.X., Hui D.S.C., Tam W.W.S., Tang J.L. Indacaterol for chronic obstructive pulmonary disease: systematic review and meta-analysis. PLoS ONE 2013; 8: e70784.

52. Cope S., Donohue J.F., Jansen J.P., Kraemer M., Capkun-Niggli G., Baldwin M. et al. Comparative efficacy of long-acting bronchodilators for COPD - a network meta-analysis. Respir Res 2013; 14: 100.

53. Koch A., Pizzichini E., Hamilton A., Hart L., Korducki L., De Salvo M.C. et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis 2014; 9: 697 - 714.

54. Decramer M., Anzueto A., Kerwin E., Kaelin T., Richard N., Crater G. et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicenter, blinded, randomized controlled trials. Lancet Respir Med 2014; 2: 472 - 86.

55. Vogelmeier C., Hederer B., Glaab T. et al. Tiotropium versus salmeterol for the prevention of exacerbations in COPD//N Engl J Med 2011; 364: 1093 - 103.

56. Decramer M.L., Chapman K.R., Dahl R. et al., INVIGORATE investigators. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study//Lancet Respir Med. 2013; 1(7): 524 - 33.

57. Wilchesky M., Ernst P., Brophy J.M., Platt R.W., Suissa S. Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. Chest 2012; 142: 305 - 11.

58. Decramer M.L., Hanania N.A., Lotvall J.O., Yawn B.P. The safety of long-acting b2-agonists in the treatment of stable chronic obstructive disease. Int J Chron Obstruct Pulmon Dis 2013; 8: 53 - 64.

59. Kew K.M., Mavergames C., Walters J.A.E. Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013; Art. No.: CD010177.

60. Karner C., Chong J., Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 7: CD009285.

61. Sims M.W., Panettieri R.A. Jr. Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2011; 6: 457 - 66.

62. Ulrik C.S. Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit. Int J Chron Obstruct Pulmon Dis 2012; 7: 673 - 8.

63. Jones P.W., Rennard S.I., Agusti A. et al. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir Res 2011; 12: 55.

64. Kerwin E., Hebert J., Gallagher N. et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J 2012; 40: 1106 - 14.

65. Donohue J.F., Niewoehner D., Brooks J. et al. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, doubleblind, placebo-controlled study. Respir Res 2014; 15: 78.

66. Sharafkhaneh A., Majid H., Gross N.J. Safety and tolerability of inhalational anticholinergics in COPD. Drug Healthc Patient Saf 2013; 5: 49 - 55.

67. Tashkin D.P., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S. et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543 - 54.

68. Wise R.A., Anzueto A., Cotton D. et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 2013; 369: 1491 - 501.

69. Appleton S., Jones T., Poole P. et al. Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 2: CD001387.

70. Appleton S., Jones T., Poole P. et al. Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 3: CD006101.

71. Karner C., Cates C.J. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 4: CD008989.

72. Decramer M., Anzueto A., Kerwin E. et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicenter, blinded, randomized controlled trials. Lancet Respir Med 2014; 2: 472 - 86.

73. Bateman E.D., Ferguson G.T., Barnes N. et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013; 42: 1484 - 94.

74. Donohue J.F., Maleki-Yazdi M.R., Kilbride S. et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med 2013; 107: 1538 - 46.

75. Vincken W., Aumann J., Chen H. et al. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Int J Chron Obstruct Pulmon Dis 2014; 9: 215 - 28.

76. Wedzicha J.A., Dahl R., Buhl R. et al. Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients. Respir Med 2014; 108: 1498 - 507.

77. Ulrik C.S. Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review. Int J Chron Obstruct Pulmon Dis 2014; 9: 331 - 8.

78. Buhl R., Maltais F., Abrahams R. et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4)//Eur Respir J. 2015; 45: 969 - 979.

79. Singh D, Jones PW, Bateman ED. et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med. 2014 Nov 18; 14: 178.

80. Beeh K.M., Westerman J., Kirsten A.M. et al. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease//Pulm Pharmacol Ther. 2015; 32: 53 - 9.

81. Wedzicha J.A., Decramer M., Ficker J.H. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomized, double-blind, parallel-group study. Lancet Respir Med 2013; 1: 199 - 209.

82. Broekhuizen B.D., Sachs A.P., Moons K.G., Cheragwandi S.A., Damste H.E., Wignands G.J. et al. Diagnostic value of oral prednisolone test for chronic obstructive pulmonary disorders. Ann Fam Med 2011; 9: 104 - 9.

83. Callahan C.M., Dittus R.S., Katz B.P. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med 1991; 114: 216 - 23.

84. Yang I.A., Clarke M.S., Sim E.H.A., Fong K.M. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 7: CD002991.

85. Suissa S., Kezouh A., Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 2010; 123: 1001 - 6.

86. Izquierdo JL, Cosio B. The dose of inhaled corticosteroids in patients with COPD: when less is better International Journal of COPD 2018: 13 3539 - 3547

87. Calverley P.M.A., Anderson A.M.A., Ferguson G.T. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775 - 89.

88. Lipson D.A., Barnhart F., Brealey N. et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. NEJM; 2018; 378: 1671 - 1680

89. Lipson D.A., Barnacle H., Birk R. et al. FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med; 2017; 196 (4): 438 - 446

90. Aaron S.D., Vandemheen K.L., Fergusson D., Maltais F., Bourbeau J., Goldstein R. et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomised trial. Ann Intern Med 2007; 146: 545 - 55.

91. Welte T., Miravitlles M., Hernandez P., Eriksson G., Peterson S., Polanowski T. et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 741 - 50.

92. Cazzola M., Ando F., Santus P., Ruggeri P., Di Marco F., Sanduzzi A. et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium to the airflow obstruction of patients with severe-to-very severe COPD. Pulm Pharmacol Ther 2007; 20: 556 - 61.

93. Karner C., Cates C.J. Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011; 3: CD008532.

94. Wedzicha J.A., Calverley P.M.A., Seemungal T.A. et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008; 177: 19 - 26.

95. Watz H., Tetzlaff K., Wouters E.F. et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial//Lancet Respir Med. 2016; 4(5): 390 - 8.

96. Vestbo J., Anderson J.A., Brook R.D. et al.; SUMMIT Investigators. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.. Lancet. 2016; 387 (10030): 1817 - 26.

97. Loke Y.K., Cavallazzi R., Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax 2011; 66: 699 - 708.

98. Chong J., Poole P., Leung B., Black P.N. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011; 5: CD002309.

99. Calverley P.M.A., Rabe K.F., Goehring U-M et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374: 685 - 94.

100. Walters J.A.E., Walters E.H., Wood-Baker R. Oral corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; 3: CD005374.

101. Schols A.M.W.J., Wesseling G., Kester A.D.M. et al. Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids. Eur Respir J 2001; 17: 337 - 42.

102. Man W.D.-C., Kemp P., Moxham J., Polkey M.I. Skeletal muscle dysfunction in COPD: clinical and laboratory observations. Clin Sci (Lond) 2009; 117: 251 - 64.

103. Barnes P.J. Theophylline. Am J Respir Crit Care Med 2013; 188: 901 - 6.

104. Zhou Y., Wang X., Zeng X., Qiu R., Xie J., Liu S. et al. Positive benefits of theophylline in a randomized, double-blind, parallelgroup, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. Respirology 2006; 11: 603 - 10.

105. Ram F.S., Jones P., Jardim J., Castro A.A., Atallah A.N., Lacasse Y. et al. Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002; 3: CD003902.

106. Rossi A., Kristufek P., Levine B.E., Thomson M.H., Till D., Kottakis J. et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002; 121: 1058 - 69.

107. Donath E., Chaudhry A., Hernandez-Aya L.F., Lit L. A metaanalysis on the prophylactic use of macrolide antibiotics for the prevention of disease exacerbations in patients with chronic obstructive pulmonary disease. Respir Med 2013; 107: 1385 - 92.

108. Albert R.K., Connett J., Bailey W.C. et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365: 689 - 98.

109. Poole P., Black P.N., Cates C.J. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 8: CD001287.

110. Cazzola M., Calzetta L., Page C. et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis//Eur Respir Rev 2015; 24(137): 451 - 61.

111. Al-Showair R.A., Tarsin W.Y., Assi K.H. et al. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help?//Respir Med 2007; 101: 2395 - 401.

112. Laube B.L., Janssens H.M., de Jongh F.H. et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011; 37: 1308 - 31.

113. Wieshammer S., Dreyhaupt J. Dry powder inhalers: which factors determine the frequency of handling errors? Respiration 2008; 75: 18 - 25.

114. Chapman K.R., Voshaar T.H., Virchow J.C. Inhaler choice in primary practice. Eur Respir Rev 2005; 14: 117 - 22.

115. Poole P.J., Chacko E., Wood-Baker R.W., Cates C.J. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 1: CD002733.

116. Sestini P., Renzoni E., Robinson S. et al. Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease//Cochrane database Syst Rev 2002; (4): CD001495

117. Van der Molen T., Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes//Primary Care Respir J 2012; 21(1): 101 - 8.

118. Mahler D.A., Decramer M., D`Urzo A. et al. Dual bronchodilatation with QVA149 reduces patient reported dyspnea in COPD: the BLAZE study Eur Respir J 2014; 43(6): 1599 - 609.

119. Calzetta L, Ritondo BL, de Marco P, Cazzola M, Rogliani P. Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies. Expert Rev Respir Med. 2021 Jan; 15(1): 143 - 152.

120. Yu A.P., A., Ponce de Leon D. et al. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J Med Econ. 2011; 14 (4): 486 - 496

121. White P., Thorntoh H., Pinnock H., Georgopoulou S., Booth H.P. Overtreatment of COPD with inhaled corticosteroids - implications for safety and costs: cross-sectional observational study. PLoS ONE 2013; 8: e75221.

122. Rossi A., Guerriero M., Corrado A.; OPTIMO/AIPO Study Group. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO)//Respir Res. 2014; 15: 77.

123. Magnussen H., Disse B., Rodriguez-Roisin R. et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD//N Engl J Med 2014; 371: 1285 - 94.

124. Chapman K.R., Hurst J.R., Frent S.M., Larbig M., Fogel R., Guerin T., Banerji D., Patalano F., Goyal P., Pfister P., Kostikas K., Wedzicha J.A. Long-term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in COPD Patients (SUNSET): a Randomized, Double-Blind, Triple-Dummy Clinical Trial. Am J Respir Crit Care Med 2018; 198: 329 - 339.

125. Авдеев С.Н., Айсанов З.Р., Архипов В.В., Белевский А.С., Лещенко И.В., Овчаренко С.И., Шмелев Е.И., Миравитлс М. Отмена ингаляционных глюкокортикостероидов у пациентов с хронической обструктивной болезнью легких.//Пульмонология. 2019; 29(3): 334 - 345.

126. Naunheim K.S., Wood D.E., Mohsenifar Z. et al. Long-term follow-up of patients receiving lung-volume reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group//Ann Thorac Surg 2006; 82: 431 - 43.

127. Orens J.B., Estenne M., Arcasoy S. et al. International guidelines for the selection of lung transplant candidates: 2006 update - a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25: 745 - 55.

128. Stoller J.K., Panos R.J., Krachman S. et al. Oxygen therapy for patients with COPD: current evidence and the long-term oxygen treatment trial//Chest 2010; 138: 179 - 87.

129. Sculley, J. A., Corbridge, S. J., Prieto-Centurion, et al., Home Oxygen Therapy for Patients With COPD: Time for a Reboot. Respiratory Care, 2019; 64(12): 1574 - 1585.

130. Ergan, B., Nava, S. Long-Term Oxygen Therapy in COPD Patients Who Do Not Meet the Actual Recommendations. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2017; 14(3): 351 - 366.

131. Jacobs, S. S., Krishnan, J. A., Lederer, D. J., et al. Home Oxygen Therapy for Adults with Chronic Lung Disease. An Official American Thoracic Society Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2020; 202(10), e121 - e141

132. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease//Am J Respir Crit Care Med 1995; 152: S77 - S120

133. Murphy P.B., Rehal S., Arbane G. et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomised clinical trial. JAMA. 2017; 317: 2177 - 86

134. Kohnlein T., Windish W., Kohler D. et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicenter, randomized controlled clinical trial//Lancet Respir Med 2014 Sep 2 (9): 698 - 705.

135. Ergan, B., Oczkowski, S., Rochwerg, B., Carlucci, A., et al. European Respiratory Society Guideline on Long-term Home Non-Invasive Ventilation for Management of Chronic Obstructive Pulmonary Disease. Eur Respir J. 2019; 54(3): 1901003.

136. Duiverman, M. L., Vonk, J. M., Bladder, G., et al. Home initiation of chronic non-invasive ventilation in COPD patients with chronic hypercapnic respiratory failure: a randomised controlled trial. Thorax. 2020; 75(3): 244 - 252.

137. Murphy, P. B., & Hart, N. (2018). Home Non-Invasive Ventilation for COPD: How, Who and When? Archivos de Bronconeumolog a, 2018; 54(3), 149 - 154

138. McEvoy R.D., Pierce R.J., Hillman D. et al. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial//Thorax 2009: 64: 561 - 6.

139. National Clinical Guideline Centre (UK). Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care. London: Royal College of Physicians (UK); 2010 Jun. (NICE Clinical Guidelines, No. 101.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK65039/

140. Higgings B.G., Powell R.M., Cooper S., Tattersfield A.E. Effect of salbutamol and ipratropium bromide on airway calibre and bronchial reactivity in asthma and chronic bronchitis. Eur Respir J 1991; 4: 415 - 20.

141. O'Driscoll B.R., Kay E.A., Taylor R.J., Weatherby H., Chetty M.C., Bernstein A. A long-term prospective assessment of home nebulizer treatment. Respir Med 1992; 86: 317 - 25.

142. Davies L., Angus R.M., Calverley P.M. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial//Lancet 1999; 354(9177): 456 - 60.

143. Maltais F., Ostinelli J., Bourbeau J. et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbation of chronic obstructive pulmonary disease: a randomized controlled trial//Am J Respir Crit Care Med 2002: 165(5): 698 - 703

144. Bafadhel M., McKenna S., Terry S. et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial//Am J Respir Crit Care Med 2012; 186(1): 48 - 55.

145. Anthonisen N.R., Manfreda J., Warren C.P. et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease//Ann Intern Med 1987; 106(2): 196 - 204.

146. Miravitlles M., Kruesmann F., Haverstock D. et al. Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis//Eur Respir J 2012; 39(6): 1354 - 60.

147. Nouira S., Marghli S., Belghith M. et al. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial//Lancet 2001; 358(9298): 2020 - 5.

148. Weis N., Almdal T. C-reactive protein - can it be used as a marker of infection in patients with exacerbation of chronic obstructive pulmonary disease//Eur J Intern Med 2006; 17: 88 - 91

149. Dev D., Sankaran E.W.R., Cunnife J. et al. Value of C-reactive protein in exacerbation of chronic obstructive pulmonary disease//Respir Med 1998; 92: 664 - 667.

150. Adams S., Luther M. Antibiotics are associated with lower relapse rates in outpatientswith acute exacerbations of chronic obstructive pulmonary disease//Chest 2000; 117: 1345 - 52.

151. Wise R. Treatment of Acute COPD Exacerbation. Last full review/revision Jun 2020. Доступно по ссылке: https://www.merckmanuals.com/professional/pulmonary-disorders/chronic-obstructive-pulmonary-disease-and-related-disorders/treatment-of-acute-copd-exacerbation

152. Miravitlles M., Espinosa C., Fernandez-Laso E. et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD//Chest 1999; 116(1): 40 - 6.

153. Soler N., Torres A., Ewig S. et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation//Am J Respir Crit Care Med1998; 157(5Pt1): 1498 - 505.

154. Robert Wilson, Antonio Anzueto, Marc Miravitlles. et. al. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur Respir J 2012; 40: 17 - 27.

155. Eller J., Ede A., Schaberg T. et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiologyand lung function//Chest 1998; 113: 1542 - 8.

156. Austin M.A., Wills K.E., Blizzard L. et al. Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial//BMJ 2010; 341: с 5462.

157. Antyn A., Guell R., Gymes J. et al. Predicting the result of noninvasive ventilation in severe acute exacerbations of patients with chronic airflow limitation//Chest 2000; 117 (3): 828 - 833.

158. Plant P.K., Owen J.L., Elliott M.W. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial//Lancet 2000; 355(9219): 1931 - 5.

159. Mehta S., Hill N.S. Noninvasive ventilation//Am J Respir Crit Care Med 2001; 163: 540 - 577.

160. Авдеев С.Н., Чучалин А.Г. Неинвазивная вентиляция легких при острой дыхательной недостаточности у больных хронической обструктивной болезнью легких//Тер. Архив 2000; 3: 59 - 65.

161. Nava S., Hill N. Non-invasive ventilation in acute respiratory failure//Lancet 2009; 374: 250 - 259.

162. Conti G., Antonelli M., Navalesi P. et al. Noninvasive vs. conventional mechanical ventilationin patients with chronic obstructive pulmonary disease after failure of medical treatment in the ward: a randomised trial//Intensive Care Med 2002; 28 (12): 1701 - 7.

163. Gladwin M.T., Pierson D.J., Mechanical ventilation of the patient with severe chronic obstructive pulmonary disease//Intensive Care Med. 1998. V. 24. P. 898 - 910

164. Esteban A., Frutos F., Tobin M.J. et al. A comparison of four methods of weaning patients from mechanical ventilation. Spanish Lung Failure Collaborative Group//N Engl J Med 1995; 332: 345 - 50.

165. Vargas F, Bui HN, Boyer A, et al: Intrapulmonary percussive ventilation in acute exacerbations of COPD patients with mild respiratory acidosis: A randomized controlled trial. Crit Care 2005; 9: R382 - R389

166. Nicolini, A., Grecchi, B., Ferrari-Bravo, M., Barlascini, C. (). Safety and effectiveness of the high-frequency chest wall oscillation vs intrapulmonary percussive ventilation in patients with severe COPD. International Journal of Chronic Obstructive Pulmonary Disease, 2018; 13: 617 - 625

167. Waschki B., Kirsten A., Holz O. et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest 2011; 140: 331 - 42.

168. Nici L., Donner C., Wouters E., et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006; 173: 1390 - 413.

169. Ries A.L., Bauldoff G.S., Carlin B.W., et al. Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest 2007; 131: 4S - 42S.

170. Puhan M.A., Gimeno-Santos E., Scharplatz M., Troosters T., Walters E.H., Steurer J. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011 Oct 5; (10): CD005305.

171. Celli B.R. Pulmonary rehabilitation in patients with COPD. Am J Respir Crit Care Med 1995; 152: 861 - 4.

172. Troosters T., Casaburi R., Gosselink R., Decramer M. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 19 - 38.

173. Puhan M.A., Busching G., Schunemann H.J., VanOort E., Zaugg C., Frey M. Interval versus continuous high-intensity exercise in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2006; 145: 816 - 25.

174. Mahler D.A.. Pulmonary rehabilitation. Chest 1998; 113: 263S - 8S.

175. Belman M.J., Botnick W.C., Nathan S.D., Chon K.H. Ventilatory load characteristics during ventilatory muscle training. Am J Respir Crit Care Med 1994; 149: 925 - 9.

176. O'Brien K., Geddes E.L., Reid W.D., Brooks D., Crowe J. Inspiratory muscle training compared with other rehabilitation interventions in chronic obstructive pulmonary disease: a systematic review update. J Cardiopulm Rehabil Prev 2008; 28: 128 - 41.

177. Heffner J.E., Fahy B., Hilling L., Barbieri C.: Outcomes of advance directive education of pulmonary rehabilitation patients. Am J Respir Crit Care Med 1997; 155: 1055 - 1059.

178. Stewart M.A.: Effective ph Heffner J.E., Fahy B., Hilling L., Barbieri C.: Outcomes of advance directive education of pulmonary rehabilitation patients. Am J Respir Crit Care Med 1997; 155: 1055 - 1059.

179. Zwerink M., Brusse-Keizer M., van der Valk P.D. et al. Self management for patients with chronic obstructive pulmonary disease//Cochrane Database Syst Rev 2014; 3(3): CD002990

180. Bischoff E.W., Hamd D.H., Sedeno M., Benedetti A., Schermer T.R., Bernard S., Maltais F., Bourbeau J.: Effects of written action plan adherence on COPD exacerbation recovery. Thorax 2011; 66: 26 - 31.

181. Van Eerd E.A., van der Meer R.M., van Schayk O.C., Kotz D. Smoking cessation for people with chronic obstructive pulmonary disease//Cochrane Database Syst Rev 2016; (8): CD010744

182. Romieu I., Riojas-Rodriguez H., Marron-Mares A.T. et al. Improved biomass stove intervention in rural Mexico: impact on the respiratory health of women//Am J Respir Crit Care Med 2009; 180: 649 - 56

183. Mathew T., Kaur A., Ross J. et al., For patients with COPD, does pneumococcal vaccination reduce the incidence of pneumococcal pneumonia?//Evidence-Based Practice 2018; 21(1): E15.

184. Sandelowsky H, Natalishvili N, Krakau I, Modin S, B, Nager A. COPD management by Swedish general practitioners - baseline results of the PRIMAIR study. Scand J Prim Health Care. 2018 Mar; 36(1): 5 - 13.

185. Jochmann A, Neubauer F, Miedinger D, Schafroth S, Tamm M, Leuppi JD. General practitioner"s adherence to the COPD GOLD guidelines: baseline data of the Swiss COPD Cohort Study. Swiss Med Wkly. 2010. 9; 140: 10.4414/smw.2010.13053.

186. , G., , R., , R. et al. Diagnosing COPD in primary care: what has real life practice got to do with guidelines?. Multidiscip Respir Med 2019; 14, 28

187. Matsunaga K, Oishi K, Miravitlles M, Anzueto A. Time To Revise COPD Treatment Algorithm. Int J Chron Obstruct Pulmon Dis. 2019; 14: 2229 - 2234.

188. Организация и проведение обучения больных хронической обструктивной болезнью легких. Метод. Рекомендации. А.С. Белевский. Атмосфера, 2003

189. Schermer T, Smeenk F, van Weel C. Referral and consultation in asthma and COPD: an exploration of pulmonologists" views. Neth J Med. 2003; 61(3): 71 - 81. PMID: 12765227

190. Oliveira AS, J, Bugalho A, M, Reis G, Marques A; GI DPOC Grupo de Interesse na Doenca Pulmonar Obstrutiva Cronica. Identification and assessment of COPD exacerbations. Pulmonology. 2017; 24: S2173 - 5115(17) 30165 - 3.

191. Walters J. A. E. et al. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease//Cochrane Database of Systematic Reviews. - 2017. - N. 1.

192. Авдеев С.Н. Длительная кислородотерапия при хронической дыхательной недостаточности. М.: ФГУ "НИИ Пульмонологии ФМБА" России, 2011. 22 с//Avdeev SN. - 2011.

193. Авдеев С.Н. Неинвазивная вентиляция легких у пациентов с хронической обструктивной болезнью легких в стационаре и домашних условиях. Пульмонология. 2017; 27(2): 232 - 249. https://doi.org/10.18093/0869-0189-2017-27-2-232-249

194. Авдеев С.Н. Обострения хронической обструктивной болезни легких: выбор антибактериальной терапии. Пульмонология. 2014; (6): 65 - 72. https://doi.org/10.18093/0869-0189-2014-0-6-65-72

195. Yoon HI, Lee CH, Kim DK, et al. Efficacy of levofloxacin versus cefuroxime in treating acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2013; 8: 329 - 334. doi: 10.2147/COPD.S41749

196. Авдеев С.Н., Гусева Н.А., Нуралиева Г.С. Эффективность метода высокочастотных колебаний грудной стенки при обострении хронической обструктивной болезни легких. Пульмонология. 2016; 26(4): 466 - 472. https://doi.org/10.18093/0869-0189-2016-26-4-466-472

197. Zeng Z, Yang D, Huang X, Xiao Z. Effect of carbocisteine on patients with COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017; 12: 2277 - 2283. Published 2017 Aug 2. doi: 10.2147/COPD.S140603